An Open-Label Extension to Investigate the Long-Term Safety, Tolerability, and Efficacy of DNL310 in Patients With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

• Protocol code: DNLI-E-0008
• EudraCT code: No aplica
• Research group: Pediatric Neurology
• Service: General Pediatrics and Specialties
• Principal investigator:  Toro Riera, Mireia del
• Pathology: Tumors
• Phase: Fase III